Fractura simultánea de ambos fémures asociadas al consumo prolongado de Alendronato. Reporte de un caso
Article Sidebar
Main Article Content
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Manuscript acceptance by the Journal implies the simultaneous non-submission to any other journal or publishing house. The RAAOT is under the Licencia Creative Commnos Atribución-NoComercial-Compartir Obras Derivadas Igual 4.0 Internacional (CC-BY-NC.SA 4.0) (http://creativecommons.org/licences/by-nc-sa/4.0/deed.es). Articles can be shared, copied, distributed, modified, altered, transformed into a derivative work, executed and publicly communicated, provided a) the authors and the original publication (Journal, Publisher and URL) are mentioned, b) they are not used for commercial purposes, c) the same terms of the license are maintained.
In the event that the manuscript is approved for its next publication, the authors retain the copyright and will assign to the journal the rights of publication, edition, reproduction, distribution, exhibition and communication at a national and international level in the different databases. data, repositories and portals.
It is hereby stated that the mentioned manuscript has not been published and that it is not being printed in any other national or foreign journal.
The authors hereby accept the necessary modifications, suggested by the reviewers, in order to adapt the manuscript to the style and publication rules of this Journal.
References
of alendronate therapy? Injury 2008;39:224-31.
2. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.
N Engl J Med 2008;358:1304-6.
3. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate
use. J Orthop Trauma 2008;22:346-50.
4. Riancho JA. Bifosfonatos en la prevención y tratamiento de la osteoporosis. En: Rapado A, Díaz Curiel M (eds.). Bifosfonatos
en las enfermedades del metabolismo óseo y mineral, Madrid: FHOEMO; 2002.
5. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential
complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
6. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, et al. Low bone mineral density is associated with bone microdamage
accumulation in postmenopausal women with osteoporosis. Bone 2007;41:378-85.
7. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate
therapy. J Bone Joint Surg Am 2009;91:2556-61.
8. Wu CC, Shih CH. Simultaneous bilateral femoral shaft fractures. J Trauma 1992;32:289-93.
9. Nork SE, Agel J, Russell GV, Mills WJ, Holt S, Routt ML, Jr. Mortality after reamed intramedullary nailing of bilateral femur
fractures. Clin Orthop Relat Res 2003;415:272-8.
10. Kane RS, Hensleigh KA, Burns EA. Bilateral pathologic femoral shaft fractures. J Trauma 2005;58:395-7.
11. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol
Metab 2008;93:2948-52